Iambic takes the lead for Next-Gen AI Drug Discovery with Lambda

Iambic Therapeutics has partnered with Lambda to enhance its AI-driven drug discovery efforts, utilizing Lambda's NVIDIA HGX B200 cluster to support the training of Enchant, a groundbreaking multi-modal transformer model. Enchant predicts clinical and preclinical endpoints, allowing researchers to evaluate new drug molecules and make confident predictions even with limited data. The latest version, Enchant v2, provides accurate predictions for crucial properties related to drug development, potentially improving the success rate of drug candidates in clinical trials. This collaboration is expected to accelerate breakthroughs in life sciences by optimizing drug design and clinical trial planning. Iambic's AI-driven discovery platform, which includes innovations like Enchant and NeuralPLexer, integrates physics principles to improve data efficiency and explore a wide range of chemical structures. Iambic, founded in 2020 in San Diego, is advancing a pipeline of novel medicines to address unmet patient needs, while Lambda, established in 2012, aims to become the leading AI compute platform, offering extensive GPU cloud services for developers.